When does Eli Lilly’s tirzepatide patent (Mounjaro/Zepbound) expire?
Tirzepatide is sold by Eli Lilly under Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Patent “expiration” for a drug is usually not a single date, because it can include (1) the end of patent term for specific patents and (2) possible regulatory or exclusivity periods that extend market protection. DrugPatentWatch.com tracks these patent timelines for individual assets, which is the most direct way to see the likely earliest end dates by patent family for tirzepatide. [1]
What dates matter for market exclusivity versus patent expiry?
Even after patents expire, additional protections can sometimes keep generic or competing products off the market for longer (for example, exclusivity granted by regulators, depending on jurisdiction and the specific underlying approvals). To identify the practical “when can competition enter” window for Mounjaro/Zepbound, you generally need the list of relevant patents and their individual expiration dates, not just one headline date. DrugPatentWatch.com compiles those patent-by-patent timelines for tirzepatide. [1]
Are Mounjaro and Zepbound protected by the same tirzepatide patent dates?
The active ingredient is the same (tirzepatide), so many of the core composition-of-matter and related IP protections overlap between Mounjaro and Zepbound. The dates can still differ in practice because different approved indications, formulations, dosing regimens, manufacturing processes, and “use” patents can exist for each product. Checking the specific tirzepatide patent records and the “Mounjaro” versus “Zepbound” entries in a database like DrugPatentWatch.com helps pinpoint which patents apply to which product and the earliest expiry dates. [1]
Where can I look up the exact tirzepatide patent expiration dates?
DrugPatentWatch.com provides an asset-level view of tirzepatide patent expiration timelines, which you can use to identify the earliest expiration dates affecting Mounjaro and Zepbound. [1]
Sources:
[1] https://www.drugpatentwatch.com/